- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05728138
Psychosocial Intervention for Suicidal Ideation in Individuals With FEP: A Feasibility Trial (CMAP-FEP)
August 25, 2023 updated by: Pakistan Institute of Living and Learning
Culturally Adapted Psychosocial Intervention for Suicidal Ideation in Individuals With First Episode Psychosis: A Feasibility Randomised Controlled Trial
To check the feasibility and acceptability of Culturally adapted Cognitive Behavioral Therapy for Psychosis (CaCBTp) and Culturally Adapted Manual Assisted Brief Psychological Intervention for Self-harm (CMAP), which we have provisionally called (CMAP Plus) for individuals experiencing Suicidal Ideation (SI) in First Episode Psychosis (FEP).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Psychosis is one of the 20 leading causes of disability worldwide, affecting 29 million people.
First Episode Psychosis (FEP) occurs at a young age and is thought to be a critical period, influencing the long-term course of the disorder.
The early course of psychosis is characterised by repeated relapses with up to 80 % relapsing within five years of an initial episode.
It has been reported that individuals diagnosed with psychosis disorders are also identified with developing experiences of self-harm, completed suicide or suicide attempt.
A systematic review on identification of correlation between self-harm/suicidality and FEP, also suggested association of suicidal ideation or self-injurious behavior though additional research is highly recommended in this particular subject Psychological therapies are widely used in the high-income countries, but very limited in LMIC like Pakistan due to factors including lack of trained mental health workers and inadequate infrastructure to support secondary mental health services.
These factors, amongst others, contribute to the significant treatment gap in LMICs like Pakistan.
There are currently no early intervention services in Pakistan and given the shortage of appropriately trained clinicians to deliver psychosocial interventions novel approaches are needed.
We have culturally adapted Cognitive Behavior therapy which demonstrated feasibility and acceptability for psychosis in Pakistan.
To address suicide specific symptoms, content will be integrated from the life after self-harm manual (CMAP.
It is a CBT based problem solving intervention for self-harm which has been adapted in Pakistan in a feasibility trial and a recently completed MRC funded large multicenter trial (n=901)
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zaib un Nisa
- Phone Number: 021-35871845
- Email: Zaibunnisa@pill.org.pk
Study Contact Backup
- Name: Ameer Bukhsh
- Phone Number: 021-35871845
- Email: ameer.bukhsh@pill.org.pk
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Individuals diagnosed with FEP, Schizophrenia or Schizoaffective disorder according to DSM-V, confirmed by treating consultant.
- Age 18-35 years able to understand written and spoken Urdu.
- A score of 1 (Mild- Frequent thoughts of being better off dead, or occasional thoughts of suicide.) on the Calgary depression Scale item 8 (Suicide) "Have you felt that life wasn't worth living? Did you ever feel like ending it all? What did you think you might do? Did you actually try?"
- Individuals with a score of 3 or more on any of the positive symptoms on the Positive and Negative Syndrome Scale (PANSS) (e.g., delusions, hallucination).
Exclusion Criteria:
- Any evidence of organic brain disease, clinically significant comorbid illness or learning disability. Participants deemed actively suicidal by their designated health professional.
- Those scoring >1 on Calgary depression Scale will be excluded and be referred to a psychiatric service.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CMAP Plus FEP
Participants with First episode of psychosis, Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT)
|
Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months.
This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
|
No Intervention: treatment as usual
Participants in this group will continue their routine treatment as prescribed by their responsible clinician.
In Pakistan TAU mostly comprise of antipsychotics with few patients having access to psychological therapies.
Research staff will record the nature and intensity of the TAU for each participant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility Indicator
Time Frame: From baseline to 12th week (end of intervention)
|
feasibility will be determined by collecting data on recruitment and retention rates. The success criterion of feasibility will be to recruit > 50% of eligible participants |
From baseline to 12th week (end of intervention)
|
Acceptability Indicator
Time Frame: From baseline to 12th week (end of intervention)
|
Intervention acceptability will be assessed using data on attendance.
Criterion for acceptability is a mean attendance rate of >70%.
|
From baseline to 12th week (end of intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive and Negative Syndrome Scale
Time Frame: From baseline to 12th week (end of intervention)
|
The Scale will examine the Positive and Negative Syndrome for Schizophrenia and is comprised of 30 items.
The 30 items of semi structured questionnaire will measure positive syndromes, like delusions, hallucinations, and conceptual disorganisation whereas negative syndromes include passive or apathetic social avoidance and blunted affect.
It will also indicate the magnitude of relation to one another and to psychopathology in generic term (e.g., anxiety, guilt, depression, and lack of insight).
|
From baseline to 12th week (end of intervention)
|
Beck Scale for Suicidal Ideation
Time Frame: From baseline to 12th week (end of intervention)
|
This is a 19-item instrument for detecting and measuring the thoughts of an individual that they might want to kill him/herself during the past week.
This scale has been used with schizophrenia, schizoaffective, or bipolar disorders
|
From baseline to 12th week (end of intervention)
|
Medication Adherence Rating Scale
Time Frame: From baseline to 12th week (end of intervention)
|
We will use MARS to check adherence to medications.
MARS is a 10-item measure.
It incorporates features of both the Drug Attitude Inventory (DAI) and the Morisky Medication Adherence Scale (MMAS).
The patient will be asked to choose the answer which best describes their behaviour or attitude towards their medication during the past week.
|
From baseline to 12th week (end of intervention)
|
Calgary Depression Scale
Time Frame: From baseline to 12th week (end of intervention)
|
The scale is specially designed to measure the depression for Psychosis, consist of nine items.
CDS will indicate the subjective and qualitative dimensions of depression in Schizophrenia
|
From baseline to 12th week (end of intervention)
|
The Work and Social Adjustment Scale
Time Frame: From baseline to 12th week (end of intervention)
|
Five items scale that measures the perceived impairment of social life, relationships, home management, work and private leisure having scores between 0 to 8 that means 0 (no impairment) and 8 (very severe impairment) with a total score of 40
|
From baseline to 12th week (end of intervention)
|
EuroQol-5 Dimensions EQ5-D
Time Frame: From baseline to 12th week (end of intervention)
|
Quality of life will be measured in five dimensions, including usual activities, anxiety/depression, pain/discomfort, self-care, and mobility.
|
From baseline to 12th week (end of intervention)
|
Client Service Receipt Inventory
Time Frame: From baseline to 12th week (end of intervention)
|
The information will be collected on the use of other health services such as (faith healers/Imams) using CSRI.
|
From baseline to 12th week (end of intervention)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Imran Chaudhry, Ziauddin Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2023
Primary Completion (Estimated)
June 30, 2024
Study Completion (Estimated)
October 30, 2024
Study Registration Dates
First Submitted
February 4, 2023
First Submitted That Met QC Criteria
February 4, 2023
First Posted (Actual)
February 14, 2023
Study Record Updates
Last Update Posted (Actual)
August 28, 2023
Last Update Submitted That Met QC Criteria
August 25, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAHAR M-CMAPPlus FEP 07
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Self Harm, First Episode Psychosis
-
Northwell HealthNational Institute of Mental Health (NIMH)RecruitingFirst Episode PsychosisUnited States
-
University of Southern CaliforniaNational Institute of Mental Health (NIMH); University of California, Los AngelesCompleted
-
Chinese University of Hong KongCompletedFirst Episode PsychosisHong Kong
-
John Jay College of Criminal Justice, City University...Indiana University School of MedicineRecruitingYouth | First Episode PsychosisUnited States
-
Northwell HealthNational Institute of Mental Health (NIMH)CompletedSchizophrenia | First Episode PsychosisUnited States
-
University of PennsylvaniaPenn Innovation in Suicide Prevention for Implementation Research (INSPIRE)...Not yet recruitingFirst-Episode Psychosis
-
Northwell HealthNational Institute of Mental Health (NIMH)RecruitingFirst Episode PsychosisUnited States
-
Nicholas BreitbordeWithdrawnPsychosis | First Episode PsychosisUnited States
-
Chonbuk National University HospitalJanssen Korea, Ltd., KoreaCompletedFirst Episode PsychosisKorea, Republic of
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH); Washington University School of... and other collaboratorsRecruiting
Clinical Trials on CMAP Plus CBT
-
Pakistan Institute of Living and LearningUniversity of ManchesterNot yet recruitingSubstance-Related Disorders | Self Harm
-
Pakistan Institute of Living and LearningNot yet recruitingSuicidal Ideation | Trauma, Psychological
-
Pakistan Institute of Living and LearningUniversity of ManchesterRecruitingChild Development | Self-harmPakistan
-
University of TrierGerman Research FoundationCompletedFeedback, PsychologicalGermany
-
VA Office of Research and DevelopmentCorporal Michael J. Crescenz VA Medical CenterRecruiting
-
University of Texas at AustinUnknownAnxiety DisordersUnited States
-
University of ReginaCanadian Institutes of Health Research (CIHR)Completed
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorder | Nightmares | Sleep DisordersUnited States
-
VA Office of Research and DevelopmentRecruiting